|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61P 35/00 | (2006.01) | ||
| C07K 16/24 | (2006.01) | ||
| A61K 39/395 | (2006.01) |
| (11) | Patento numeris | 3328425 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 16750495.0 |
| Europos patento paraiškos padavimo data | 2016-07-27 | |
| (97) | Europos patento paraiškos paskelbimo data | 2018-06-06 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-08-25 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/IB2016/054487 |
| Data | 2016-07-27 |
| (87) | Numeris | WO 2017/017623 |
| Data | 2017-02-02 |
| (30) | Numeris | Data | Šalis |
| 201562198384 P | 2015-07-29 | US | |
| 201662352637 P | 2016-06-21 | US |
| (72) |
FJAELLSKOG, Marie-Louise , US
CAMERON, John , US
CAO, Zhu , US
CIPOLLETTA, Daniela , US
MACISAAC, Kenzie , US
|
| (73) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | COMBINED USE OF ANTI PD-1 AND ANTI M-CSF ANTIBODIES IN THE TREATMENT OF CANCER |
| COMBINED USE OF ANTI PD-1 AND ANTI M-CSF ANTIBODIES IN THE TREATMENT OF CANCER |